R
Rudolf Pfister
Researcher at Novartis
Publications - 16
Citations - 1522
Rudolf Pfister is an academic researcher from Novartis. The author has contributed to research in topics: Ultraviolet light & Blood proteins. The author has an hindex of 9, co-authored 16 publications receiving 1355 citations.
Papers
More filters
Journal ArticleDOI
A good practice guide to the administration of substances and removal of blood, including routes and volumes
Karl-Heinz Diehl,Robin Hull,David B. Morton,Rudolf Pfister,Yvon Rabemampianina,David Smith,Jean-Marc Vidal,Cor Van De Vorstenbosch +7 more
TL;DR: An initiative between the European Federation of Pharmaceutical Industries Associations and the European Centre for the Validation of Alternative Methods to provide the researcher in the safety evaluation laboratory with an up‐to‐date, easy‐to-use set of data sheets to aid in the study design process.
Patent
Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
Alfred Sallmann,Rudolf Pfister +1 more
TL;DR: SUBSTITUTED 2-ANILINOPHENYLACETIC ACIDS, their ESTERS and SALTS have DESIRABLE ABSORPTION PATTERNS for PROTECTING the SKIN AGAINST the IRRITATING EFFECT of ULTRAVIOLET LIGHT as mentioned in this paper.
Journal ArticleDOI
Blood collection from the sublingual vein in mice and hamsters: a suitable alternative to retrobulbar technique that provides large volumes and minimizes tissue damage
TL;DR: Sublingual venepuncture can be recommended as a suitable, alternative blood collection technique, because of the reduced risk of tissue damage in mice and hamsters.
Journal ArticleDOI
Preclinical safety evaluation using nonrodent species: an industry/welfare project to minimize dog use.
David M. Smith,Caren Broadhead,Gerard Descotes,Richard Fosse,Ruediger Hack,Klaus Krauser,Rudolf Pfister,Barry Phillips,Yvon Rabemampianina,James Sanders,Sue Sparrow,Markus Stephan-Gueldner,Soren Dyring Jacobsen +12 more
TL;DR: This review of the dog, the primary nonrodent species used in toxicology, and its use in the safety evaluation of pharmaceuticals, provides data on the number used in particular projects in an effort to establish a baseline from which some minimization can be measured.
Journal ArticleDOI
Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
David M. Smith,Robert Combes,Olympe Depelchin,Soren Dyring Jacobsen,Ruediger Hack,Joerg Luft,Lieve Lammens,Friedrich von Landenberg,Barry Phillips,Rudolf Pfister,Yvon Rabemampianina,Susan Sparrow,Claudia Stark,Markus Stephan-Gueldner +13 more
TL;DR: The implementation of such an optimised design is believed to result in a reduction in the overall numbers of animals used for safety testing, without jeopardising the scientific rationale and usefulness of the studies for informing the conduct of later regulatory studies.